A Real-world Study: Efficacy and Safety of Selinexor-based Regimens for Non-Hodgkin Lymphoma
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study aims to observe and explore the efficacy and safety of selinexor-based regimen in patients with Non-Hodgkin lymphoma
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Know and voluntarily sign the Informed Consent Form (ICF)
• Clinically confirmed DLBCL, T or NK cell lymphoma
• Patients with DLBCL or T or NK cell lymphoma who have used selinexor-based therapy in the past 3 months are included
• Cooperate with clinical diagnosis and treatment management, and provide disease-related past medical history materials
Locations
Other Locations
China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING
Shanghai
The First Affiliated Hospital of Soochow University
RECRUITING
Suzhou
Union Hospital Affiliated to Huazhong University of Science and Technology
RECRUITING
Wuhan
Contact Information
Primary
Weili Zhao, Prof.
zwl_trial@163.com
+862164370045
Backup
Pengpeng Xu, Prof.
pengpeng_xu@126.com
+862164370045
Time Frame
Start Date: 2022-12-15
Estimated Completion Date: 2025-10-18
Participants
Target number of participants: 250
Treatments
selinexor-based regimens
This study is a real-world study to explore the safety and efficacy of selinexor-based therapy in patients with lymphoma. It is planned to enroll 250 patients with lymphoma, including 150 patients with diffuse large B-cell lymphoma and 100 patients with peripheral T and NK/T-cell lymphoma.
Related Therapeutic Areas
Sponsors
Leads: Ruijin Hospital